Innoviva Q3 revenue up 20%, net income surges

Innoviva

05/11/2025 22:26

Overview

Innoviva Q3 2025 total revenue grows 20% yr/yr, driven by royalties and product sales

Net income for Q3 2025 soars to $89.9 mln from $1.2 mln last year

Company announces $125 mln share repurchase program

Outlook

Company did not provide specific financial guidance for future quarters or fiscal year

Result Drivers

ROYALTIES GROWTH - Co reports 5% growth in royalties portfolio, highlighting resilience

IST SALES GROWTH - IST achieved 52% yr/yr growth in U.S. net product sales

ZEVTERA LAUNCH - Early market receptivity for ZEVTERA following U.S. launch over summer

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Royalty Revenue
$59.9 mln
Q3 Net Income
$89.91 mln
Q3 Pretax Profit
$97.82 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Innoviva Inc is $35.00, about 48.1% above its November 4 closing price of $18.15

The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release: ID:nBw2x90rxa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)